Editing Iron(II,III) oxide (section)

==Uses==
{{Infobox drug
| drug_name         = Ferumoxytol
| INN               = 
| type              = <!-- empty -->
| image             = 
| width             = 
| alt               = 
| caption           =

<!-- Clinical data -->
| pronounce         = 
| tradename         = Feraheme, Rienso
| Drugs.com         = {{drugs.com|monograph|ferumoxytol}}
| MedlinePlus       = a614023
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = Yes
| DailyMedID        = Ferumoxytol
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US      = N
| pregnancy_US_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Ferumoxytol (Feraheme) Use During Pregnancy | website=Drugs.com | date=15 May 2020 | url=https://www.drugs.com/pregnancy/ferumoxytol.html | access-date=14 September 2020}}</ref>
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Intravenous|Intravenous infusion]]
| class             = 
| ATCvet            = 
| ATC_prefix        = None
| ATC_suffix        = 
| ATC_supplemental  =

<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  = 
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment  = 
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  = 
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  = 
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  = 
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  = 
| legal_US          = Rx-only
| legal_US_comment  = <ref name="Feraheme FDA label">{{cite web | title=Feraheme- ferumoxytol injection | website=DailyMed | date=9 July 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b | access-date=14 September 2020}}</ref>
| legal_EU          = Rx-only
| legal_EU_comment  = <ref name="Rienso EPAR">{{cite web | title=Rienso EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/rienso | access-date=14 September 2020}}</ref>
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  = 
| legal_status      = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action = 
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 1309-38-2
| CAS_supplemental  = 
| PubChem           = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = 
| DrugBank          = DB06215
| ChemSpiderID_Ref  = 
| ChemSpiderID      = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CLH5FT6412
| KEGG_Ref          = 
| KEGG              = D04177
| ChEBI_Ref         = 
| ChEBI             = 46726
| ChEMBL_Ref        = 
| ChEMBL            = 
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          =

<!-- Chemical and physical data -->
| IUPAC_name        = iron(2+);iron(3+);oxygen(2-)
| Fe = 3 | O = 4
| SMILES            = [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3]
| StdInChI          = 1S/3Fe.4O/q+2;2*+3;4*-2
| StdInChI_comment  = 
| StdInChIKey       = WTFXARWRTYJXII-UHFFFAOYSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

Fe<sub>3</sub>O<sub>4</sub> is used as a black pigment and is known as ''C.I pigment black 11'' (C.I. No.77499) or [[Mars Black (pigment)|Mars Black]].<ref name = "Buxbaum"/>

Fe<sub>3</sub>O<sub>4</sub> is used as a catalyst in the [[Haber process]] and in the [[water-gas shift reaction]].<ref name = "Lee">Sunggyu Lee (2006)  Encyclopedia of Chemical Processing CRC Press {{ISBN|0-8247-5563-4}}</ref> The latter uses an HTS (high temperature shift catalyst) of iron oxide stabilised by [[chromium oxide]].<ref name = "Lee"/> This iron–chrome catalyst is reduced at reactor start up to generate Fe<sub>3</sub>O<sub>4</sub> from α-Fe<sub>2</sub>O<sub>3</sub>  and Cr<sub>2</sub>O<sub>3</sub> to CrO<sub>3</sub>.<ref name = "Lee"/>

[[Bluing (steel)|Bluing]] is a [[Passivation (chemistry)|passivation]] process that produces a layer of Fe<sub>3</sub>O<sub>4</sub> on the surface of steel to protect it from rust.  Along with sulfur and aluminium, it is an ingredient in steel-cutting [[thermite]].{{citation needed|date=September 2020}}

=== Medical uses ===

Nano particles of Fe<sub>3</sub>O<sub>4</sub> are used as contrast agents in [[Magnetic resonance imaging|MRI scanning]].<ref>{{cite journal | vauthors = Babes L, Denizot B, Tanguy G, Jallet P | title = Synthesis of Iron Oxide Nanoparticles Used as MRI Contrast Agents: A Parametric Study | journal = Journal of Colloid and Interface Science | volume = 212 | issue = 2 | pages = 474–482 | date = April 1999 | pmid = 10092379 | doi = 10.1006/jcis.1998.6053 | bibcode = 1999JCIS..212..474B }}</ref>

Ferumoxytol, sold under the brand names Feraheme and Rienso, is an [[intravenous]] Fe<sub>3</sub>O<sub>4</sub> preparation for treatment of [[anemia]] resulting from [[chronic kidney disease]].<ref name="Feraheme FDA label"/><ref name="Rienso EPAR"/><ref name="schwenk2010">{{cite journal |vauthors=Schwenk MH |title=Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease |journal= Pharmacotherapy |volume=30 |issue=1 |pages=70–79 |date=January 2010 |pmid=20030475 |doi=10.1592/phco.30.1.70 |s2cid=7748714 |url=http://www.medscape.com/viewarticle/715178|url-access=subscription }}</ref><ref name="FDA approval">{{cite web |title=Drug Approval Package: Feraheme (Ferumoxytol) Injection NDA #022180 |website=U.S. [[Food and Drug Administration]] (FDA) |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022180s000TOC.cfm |access-date=14 September 2020}}<br/>{{cite web | vauthors = Rieves D |date=June 23, 2009 |title=Application Number: 22-180 |publisher=Center for Drug Evaluation and Research |type=Summary Review |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022180s000_SumR.pdf}}</ref> Ferumoxytol is manufactured and globally distributed by [[AMAG Pharmaceuticals]].<ref name="Feraheme FDA label"/><ref name="FDA approval"/>